Cost-effectiveness of atrial fibrillation screening in Canadian community practice

Figures

• 

  Figure 1. Deterministic sensitivity results—incremental net benefit per patient (screening vs no screening). The vertical line intersecting the incremental net benefit (INB) per patient at Can$1039 dollars (based on a willingness-to-pay threshold of Can$50,000 per quality-adjusted life-year) with all parameters set to base-case assumptions. As each parameter is varied across the range provided in parentheses in the left-hand column, bars represent the range of incremental cost-effectiveness ratio values obtained. Black bars represent the effect of decreasing the parameter relative to its base-case value. Gray bars represent the effect of increasing the parameter relative to its base-case value. For example, the INB decreased to Can$769 when the proportion of patients with nonvalvular atrial fibrillation (NVAF) eligible for oral anticoagulation (OAC) therapy was decreased to 62.8% from the base case of 82.7%, and increased to Can$1264 when the proportion of OAC eligible patients was increased to 100%. Larger bars suggest that INB is more sensitive to the specific parameter, and smaller bars suggest that INB is less sensitive to the parameter. The most influential parameters are found at the…

• 

  Figure 2. Impact of reimbursement for screening on the incremental cost-effectiveness ratio (ICER) vs no screening. QALY = quality-adjusted life-year.